



Bifidobacterium pseudolongum; 11662

Cat. No.: LBGF-0722-GF13

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	<i>Bifidobacterium pseudolongum</i> is the most frequent species in animal gut. It is a potential probiotic for the treatment of obesity in humans and the development of probiotic production s.
Target	<i>Bifidobacterium</i>
Genus	<i>Bifidobacterium</i>
Strain Designation	O2-2
Application	Study and research
Type Strain	No
Culture Medium	BBL
Culture Conditions	37°C; Anaerobic
Source	Pig faeces
Risk Group	1
Product Format	Freeze-dried
Packaging	Ampoule tube
Storage	-80°C

TARGET INTRODUCTION

Introduction

Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They were originally isolated from the faeces of breast-fed infants, members of the genus *Bifidobacterium* are commonly found in the GI tract of mammals. In humans, *Bifidobacterium* resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including *Bifidobacterium*. Data from mouse models and clinical trials indicate that *Bifidobacterium* may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. *Bifidobacterium* have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.

Alternative Names

Bifidobacterium pseudolongum; 11662